학술논문
Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS)
Document Type
article
Author
Seonaidh Cotton; Graham Devereux; Hassan Abbas; Andrew Briggs; Karen Campbell; Rekha Chaudhuri; Gourab Choudhury; Dana Dawson; Anthony De Soyza; Shona Fielding; Simon Gompertz; John Haughney; Chim C. Lang; Amanda J. Lee; Graeme MacLennan; William MacNee; Kirsty McCormack; Nicola McMeekin; Nicholas L. Mills; Alyn Morice; John Norrie; Mark C. Petrie; David Price; Philip Short; Jorgen Vestbo; Paul Walker; Jadwiga Wedzicha; Andrew Wilson; Brian J. Lipworth
Source
Trials, Vol 23, Iss 1, Pp 1-16 (2022)
Subject
Language
English
ISSN
1745-6215
Abstract
Abstract Background Chronic obstructive pulmonary disease (COPD) is associated with significant morbidity, mortality and healthcare costs. Beta blockers are well-established drugs widely used to treat cardiovascular conditions. Observational studies consistently report that beta blocker use in people with COPD is associated with a reduced risk of COPD exacerbations. The bisoprolol in COPD study (BICS) investigates whether adding bisoprolol to routine COPD treatment has clinical and cost-effective benefits. A sub-study will risk stratify participants for heart failure to investigate whether any beneficial effect of bisoprolol is restricted to those with unrecognised heart disease. Methods BICS is a pragmatic randomised parallel group double-blind placebo-controlled trial conducted in UK primary and secondary care sites. The major inclusion criteria are an established predominant respiratory diagnosis of COPD (post-bronchodilator FEV1